Cardiovascular diseases in gout and urate-lowering therapy


DOI: https://dx.doi.org/10.18565/therapy.2021.1.108-115

Eliseev M.S.

V.A. Nasonova Research Institute of Rheumatology, Moscow
Abstract. Elevated serum uric acid levels precede sodium monourate crystals formation and gout clinical manifestations. In addition, according to epidemiological studies and meta-analyzes data, hyperuricemia (HU) is associated with arterial hypertension, ischemic heart disease, and chronic heart failure. In addition to musculoskeletal system damage, the development of gout is associated with an increased risk of myocardial infarction, cerebrovascular accident and death from cardiovascular disease (CVD). Urate-lowering therapy, in addition to lowering serum urate levels, helps to suppress systemic inflammation, reduce oxidative stress and the formation of peroxidation products, has a beneficial effect on endothelial function, and, as expected, can lead to decrease in overall and cardiovascular mortality. The review provides data on the mechanisms underlying the development of CVD in case of gout and HU, as well as the potential cardioprotective effects of urate-lowering therapy.
Keywords: gout, hyperuricemia, cardiovascular diseases, allopurinol, febuxostat
Read entire article

Literature


  1. Townsend N., Wilson L., Bhatnagar P. et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016; 37(42): 3232–45. doi: 10.1093/eurheartj/ehw334.

  2. Benjamin E.J., Blaha M.J., Chiuve S.E. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A report from the American Heart Association. Circulation. 2017; 135(10): e146–e603. doi: 10.1161/CIR.0000000000000485.

  3. World Health Organization. Cardiovascular Diseases (CVDs). Available at: http://www.who.int/ mediacentre/factsheets/fs317/en/ (date of access – 20.01.2021).

  4. Netea M.G., Balkwill F., Chonchol M. et al. A guiding map for inflammation. Nat Immunol. 2017; 18(8): 826–31. doi: 10.1038/ni.3790.

  5. Da Silva Domingues V., Rodrigues A.M., Dias S.S. et al. Increased short-term risk of cardiovascular events in inflammatory rheumatic diseases: results from a population-based cohort. Rheumatol Int. 2021; 41(2): 311–18. doi: 10.1007/s00296-020-04754-7.

  6. Choi H.K., Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007; 116(8): 894–900. doi: 10.1161/CIRCULATIONAHA.107.703389.

  7. Krishnan E., Baker J.F., Furst D.E., Schumacher H.R. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006; 54(8): 2688–96. doi: 10.1002/art.22014.

  8. Елисеев М.С., Денисов И.С., Маркелова Е.И. с соавт. Независимые факторы риска развития тяжелых сердечно-сосудистых осложнений у мужчин с подагрой: результаты 7-летнего проспективного наблюдения. Терапевтический архив. 2017; 5: 10–19. [Eliseev M.S., Denisov I.S., Markelova E.I. et al. Independent risk factors for severe cardiovascular events in male patients with gout: Results of a 7-year prospective study. Terapevticheskiy arkhiv = Therapeutic archive. 2017; 5: 10–19 (In Russ.)]. doi: https://dx.doi.org/10.17116/terarkh201789510-19.

  9. Zhu Y., Pandya B.J., Choi H.K. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012; 125(7): 679–87.e1. doi: 10.1016/j.amjmed.2011.09.033.

  10. Fang J., Alderman M.H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000; 283(18): 2404–10. doi: 10.1001/jama.283.18.2404.

  11. Li M., Hu X., Fan Y. et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep. 2016; 6: 19520. doi: 10.1038/srep19520.

  12. Kim S.Y., Guevara J.P., Kim K.M. et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010; 62(2): 170–80. doi: 10.1002/acr.20065.

  13. Liang L., Hou X., Bainey K.R. et al. The association between hyperuricemia and coronary artery calcification development: A systematic review and meta-analysis. Clin Cardiol. 2019; 42(11): 1079–86. doi: 10.1002/clc.23266.

  14. Franse L.V., Pahor M., Di Bari M. et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens. 2000; 18(8): 1149–54. doi: 10.1097/00004872-200018080-00021.

  15. Bardin T., Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014; 26(2): 186–91. doi: 10.1097/BOR.0000000000000028.

  16. Desideri G., Virdis A., Casiglia E., Borghi C. Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension. Exploration into uric and cardiovascular disease: Uric Acid Right for heArt Health (URRAH) project, a study protocol for a retrospective observational study. High Blood Press Cardiovasc Prev. 2018; 25(2): 197–202. doi: 10.1007/s40292-018-0250-7.

  17. Calvo R.Y., Araneta M.R., Kritz-Silverstein D. et al. Relation of serum uric acid to severity of and progression of coronary artery calcium in postmenopausal white and Filipino women (from The Rancho Bernardo Study). Am J Cardiol. 2014; 113(7): 1153–58. doi: 10.1016/j.amjcard.2013.12.022.

  18. Ndrepepa G., Cassese S., Braun S. et al. A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease. Nutr Metab Cardiovasc Dis. 2013; 23(12): 1195–201. doi: 10.1016/j.numecd.2013.03.005.

  19. Kolz M., Johnson T., Sanna S. et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009; 5(6): e1000504. doi: 10.1371/journal.pgen.1000504.

  20. Yu S., Yang H., Guo X. et al. Hyperuricemia is independently associated with left ventricular hypertrophy in postmenopausal women but not in pre-menopausal women in rural Northeast China. Gynecol Endocrinol. 2015; 31(9): 736–41. doi: 10.3109/09513590.2015.1056730.

  21. Grayson P.C., Kim S.Y., LaValley M., Choi H.K. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011; 63(1):102–10. doi: 10.1002/acr.20344.

  22. Viazzi F., Rebora P., Giussani M. et al. Increased serum uric acid levels blunt the antihypertensive efficacy of lifestyle modifications in children at cardiovascular risk. Hypertension. 2016; 67(5): 934–40. doi: 10.1161/HYPERTENSIONAHA.115.06852.

  23. Cicero A.F., Rosticci M., Fogacci F. et al. High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. Eur J Intern Med. 2017; 37: 38–42. doi: 10.1016/j.ejim.2016.07.026.

  24. Mazzali M., Hughes J., Kim Y.G. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001; 38(5): 1101–06. doi: 10.1161/hy1101.092839.

  25. Nakagawa T., Mazzali M., Kang D.H. et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol. 2003; 23(1): 2–7. doi: 10.1159/000066303.

  26. Sanchez-Lozada L.G., Tapia E., Bautista-Garcia P. et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2008; 294(4): F710–8. doi: 10.1152/ajprenal.00454.2007.

  27. Wang J., Qin T., Chen J. et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One.2014; 9: e114259. doi: 10.1371/journal.pone.0114259.

  28. Feig D.I., Johnson R.J. Hyperuricemia in childhood primary hypertension. Hypertension. 2003; 42(3): 247–52. doi: 10.1161/01.HYP.0000085858.66548.59.

  29. Soletsky B., Feig D.I. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012; 60(5):1148–56. doi: 10.1161/HYPERTENSIONAHA.112.196980.

  30. McMullan C.J., Borgi L., Fisher N. et al. Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: A randomized controlled trial. Clin J Am Soc Nephrol. 2017; 12(5): 807–16. doi: 10.2215/CJN.10771016.

  31. Beattie C.J., Fulton R.L., Higgins P. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension. 2014; 64(5): 1102–07. doi: 10.1161/HYPERTENSIONAHA.114.03953.

  32. Higgins P., Dawson J., Lees K.R. et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012; 30(4): 217–26. doi: 10.1111/j.1755-5922.2011. 00277.x.

  33. Scheepers L.E., Wei F.F., Stolarz-Skrzypek K. et al. Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: a population study. J Hypertens. 2016; 34(11): 2147–54. doi: 10.1097/HJH.000000000 0001077.

  34. Желябина О.В., Елисеев М.С. Некоторые потенциальные возможности применения ингибиторов ксантиноксидазы. Современная ревматология. 2019; 1: 114–120. [Zhelyabina O.V., Eliseev M.S. Some opportunities of using xanthine oxidase inhibitors. Sovremennaya revmatologiya = Modern rheumatology. 2019; 1: 114–120 (In Russ.)]. doi: https://dx.doi.org/10.14412/1996-7012-2019-1-114-120.

  35. Singh J.A. When gout goes to the heart: does gout equal a cardiovascular disease risk factor? Ann Rheum Dis. 2015; 74(4): 631–34. doi: 10.1136/annrheumdis-2014-206432.

  36. Насонов Е.Л., Елисеев М.С. Роль интерлейкина-1 в развитии заболеваний человека. Научно-практическая ревматология. 2016; 1: 60–77. [Nasonov E.L., Eliseev M.S. Role of interleukin 1 in the development of human diseases. Nauchno-prakticheskaya revmatologiya = Rheumatology science and practice. 2016; 1: 60–77 (In Russ.)]. doi: https://dx.doi.org/10.14412/1995-4484-2016-60-77.

  37. Kotur-Stevuljevic J., Memon L., Stefanovic A. et al. Correlation of oxidative stress parameters and inflammatory markers in coronary artery disease patients. Clin Biochem. 2007; 40(3–4): 181–87. doi: 10.1016/j.clinbiochem.2006.09.007.

  38. Tsutsumi Z., Moriwaki Y., Takahashi S. et al. Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy. Clin Chim Acta. 2004; 339 (1–2): 117–22. doi: 10.1016/j.cccn.2003.09.019

  39. Елисеев М.С., Желябина О.В., Мукагова М.В., Насонов Е.Л. Клинический опыт применения блокатора интерлейкина-1β канакинумаба у больных хронической тофусной подагрой: купирование артрита и профилактика обострений при назначении аллопуринола. Современная ревматология. 2015; 2: 16–22. [Eliseev M.S., Zhelyabina O.V., Mukagova M.V., Nasonov E.L. Clinical experience with the interleukin-1β blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopurinol is used. Sovremennaya revmatologiya = Modern rheumatology. 2015; 2: 16–22 (In Russ.)]. doi: https://dx.doi.org/10.14412/1996-7012-2015-2-16-22.

  40. Solomon D.H., Glynn R.J., MacFadyen J.G. et al Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: Exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018; 169(8): 535–42. doi: 10.7326/M18-1167.

  41. Kuo C.F., See L.C., Luo S.F. et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxf). 2010; 49(1): 141–46. doi: 10.1093/rheumatology/kep364.

  42. De Vera M.A., Rahman M.M., Bhole V. et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010; 69(6): 1162–64. doi: 10.1136/ard.2009.122770.

  43. Singh J.A., Ramachandaran R., Yu S. et al. Is gout a risk equivalent to diabetes for stroke and myocardial infarction? A retrospective claims database study. Arthritis Res Ther. 2017; 19(1): 228. doi: 10.1186/s13075-017-1427-5.

  44. Choi H.K., Ford E.S., Li C., Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheumatol. 2007; 57(1): 109–15. doi: 10.1002/art.22466.

  45. Perez-Ruiz F., Martínez-Indart L., Carmona L. et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Annals of the Rheumatic Diseases. 2013; 73(1): 177–82. doi: 10.1136/annrheumdis-2012-202421.

  46. Елисеев М.С., Новикова А.М. Коморбидность при подагре и гиперурикемии: распространенность, причины, перспективы уратснижающей терапии. Терапевтический архив. 2019; 5: 120–128. [Eliseev M.S., Novikova A.M. Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy. Terapevticheskiy arkhiv = Therapeutic archive. 2019; 5: 120–128 (In Russ.)]. doi: https://dx.doi.org/10.26442/00403660.2019.05.000232.

  47. Richette P., Doherty M., Pascual E. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76(1): 29–42. doi: 10.1136/annrheumdis-2016-209707.

  48. Клинические рекомендации. Подагра. Ассоциация ревматологов России. 2018. Доступ: http://cr.rosminzdrav.ru/schema/251 (дата обращения – 20.01.2021). [Clinical guidelines. Gout. Association of Rheumatologists of Russia. 2018. Available at: http://cr.rosminzdrav.ru/schema/251 (date of access – 20.01.2021) (In Russ.)].

  49. Latourte A., Pascart T., Flipo R.M. et al. 2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares. Joint Bone Spine. 2020; 87(5): 387–93. doi: 10.1016/j.jbspin.2020.05.001.

  50. Perez Ruiz F., Richette P., Stack A.G. et al. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019; 5(2): e001015. doi: 10.1136/rmdopen-2019-001015.

  51. Chen J.H., Lan J.L., Cheng C.F. et al. Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: A case-matched cohort study. J. Rheumatol. 2015; 42(9): 1694–701. doi: 10.3899/jrheum.141542.

  52. White W.B., Saag K.G., Becker M.A. et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018; 378(13): 1200–10. doi: 10.1056/NEJMoa1710895.

  53. Елисеев М.С. Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям. Научно-практическая ревматология. 2017; 6: 600–609. [Eliseev M.S. Updated eular guidelines for the management of gout. Comments on certain items. Nauchno-prakticheskaya revmatologiya = Rheumatology science and practice. 2017; 6: 600–609 (In Russ.)]. doi: https://dx.doi.org/10.14412/1995-4484-2017-600-609.

  54. Елисеев М.С. Комментарии к обновленным рекомендациям Американской коллегии ревматологов по лечению подагры. Уратснижающие препараты (часть 1). Современная ревматология. 2020; 3: 117–124. [Eliseev M.S. Commentaries on the updated American College of Rheumatology guidelines for the management of gout. Urate-lowering drugs (Part 1). Sovremennaya revmatologiya = Modern rheumatology. 2020; 3: 117–24 (In Russ.)]. doi: https://dx.doi.org/10.14412/1996-7012-2020-3-117-124.

  55. Елисеев М.С., Новикова А.М. По следам исследования CARES: сердечно-сосудистая безопасность фебуксостата. РМЖ. 2020; 7: 39–42. [Eliseev M.S., Novikova A.M. CARES study: cardiovascular safety of febuxostat. Russkiy meditsinskiy zhurnal = Russian medical journal. 2020; 7: 39–42 (In Russ.)].

  56. Zhang M., Solomon D.H., Desai R.J. et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: Population-based cohort study. Circulation. 2018; 138(11): 1116–26. doi: 10.1161/CIRCULATIONAHA.118.033992.

  57. Mackenzie I.S., Ford I., Nuki G. et al. FAST Study Group. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020; 396(10264): 1745–57. doi: 10.1016/S0140-6736(20)32234-0.


About the Autors

Maksim S. Eliseev, PhD, senior researcher, head of microcrystalline arthritis laboratory of V.A. Nasonova Research Institute of Rheumatology. Address: 115522, Moscow, 34А Kashirskoe avenue. Tel.: +7 (903) 590-98-49. E-mail: elicmax@rambler.ru. ORCID: 0000-0003-1191-5831

Back to Content

Бионика Медиа